Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA9 | Q16790 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL815927 | 0.94 | MAPT (0.45) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL816053 | 0.94 | MAPT (0.47) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL815896 | 0.91 | MAPT (0.49) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL1951824 | 0.91 | MAPT (0.51) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL30599638 | 0.91 | MAPT (0.51) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL19982370 | 0.90 | KMT2A (0.52) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL16425816 | 0.89 | KMT2A (0.53) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL16885049 | 0.89 | KMT2A (0.53) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL19982368 | 0.89 | KMT2A (0.53) | MAPTKMT2AMEN1CA12CA9 | |
| SCHEMBL16019248 | 0.88 | KMT2A (0.44) | MAPTKMT2AMEN1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325168-B1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORP (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8512597-B2 | Polymerizable optically active imide compound and polymerizable composition containing the compound | ADEKA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| US-8057701-B2 | Trifunctional (meth)acrylate compound and polymerizable composition containing same | ADEKA CORPORATION (JP) | 2011-11-15 | — | — | US | disclosed |
| EP-2325168-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | Adeka Corporation (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | ADEKA CORPORATION (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | ADEKA CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110108765-A1 | POLYMERIZABLE OPTICALLY ACTIVE IMIDE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING THE COMPOUND | H1-4, XPO4, F12 | MAPT 2630/4885KMT2A 3009/4885MEN1 264/4885 |
| US-20110037025-A1 | TRIFUNCTIONAL (METH)ACRYLATE COMPOUND AND POLYMERIZABLE COMPOSITION CONTAINING SAME | PYM1, MT-CO1, MAT1A | MAPT 1180/4885KMT2A 1215/4885MEN1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.